Arecor Therapeutics PLC chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.05
Dividend & YieldN/A£ (N/A)
Beta N/A
Market capitalization 71.64M
Operating cash flow -8.07M
ESG Scores unknown

Company description

Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo, a ready-to-use glucagon auto-injector pen that is used to treat hypoglycaemia in patients with diabetes; and specialty hospital care products. In addition, the company is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2019-05-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 277.43k -127.09k 363k 838k
Total Cashflows From Investing Activities -64.55k -22.89k -49k -68k
Net Borrowings -87.03k -119.82k 1.86M 2.39M
Total Cash From Financing Activities 5.32M -131.02k 1.77M 20.93M
Change To Operating Activities
Issuance Of Stock 5.67M 1.87k 20M 20M
Net Income -2.44M -2.19M -2.75M -6.17M
Change In Cash 2.74M -639.77k -176k 15.42M
Effect Of Exchange Rate -5.95k -27.06k -43k 5k
Total Cash From Operating Activities -2.5M -458.8k -1.86M -5.45M
Depreciation 166.93k 151.53k 168k 171k
Change To Account Receivables -312.3k 445.95k 384k -1.26M
Other Cashflows From Financing Activities -266.94k -13.07k -83k -1.46M
Change To Netincome -212.94k 1.26M -20k 967k
Capital Expenditures -73.13k -32.3k -52k -69k

Income Statement 2019-05-31 2019-12-31 2020-12-31 2021-12-31
Research Development 3.09M 3.56M 3.94M 5.39M
Income Before Tax -2.87M -2.69M -3.51M -6.95M
Net Income -2.44M -2.19M -2.75M -6.17M
Selling General Administrative 1.42M 1.61M 1.64M 2.39M
Gross Profit 747.67k 1.89M 1.7M 1.16M
Ebit -2.86M -2.69M -3.43M -5.98M
Operating Income -2.86M -2.69M -3.43M -5.98M
Interest Expense -23.98k -13.07k -82k -22k
Income Tax Expense -435.09k -502.29k -760k -776k
Total Revenue 747.67k 1.89M 1.7M 1.16M
Cost Of Revenue
Total Other Income ExpenseNet -15.4k -3.66k -84k -968k
Net Income From Continuing Ops -2.44M -2.19M -2.75M -6.17M
Net Income Applicable To Common Shares -2.44M -2.19M -2.75M -6.17M

Balance Sheet Statement 2019-05-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 1.23M 1.1M 3.51M 2.37M
Total Stockholder Equity 4.22M 3.21M 774k 18.55M
Other Current Liabilities 244.4k 302.98k 147k 457k
Total Assets 5.45M 4.31M 4.28M 20.92M
Common Stock 25.64k 26.73k 27k 278k
Other Current Assets
Retained Earnings -7.86M -9.14M -11.89M -17.05M
Treasury Stock 458.83k 727.01k 1.04M 11.97M
Cash 3.45M 3.07M 2.9M 18.32M
Total Current Liabilities 1.11M 1.04M 1.41M 2.27M
Other Stockholder Equity 458.83k 727.01k 1.04M 11.97M
Property, Plant, and Equipment 353.07k 295.12k 376k 328k
Total Current Assets 5M 3.92M 3.82M 20.52M
Net Tangible Assets 4.16M 3.16M 736k 18.52M
Net Receivables 1.5M 811.32k 860k 1.57M
Accounts Payable 567.98k 365.65k 465k 518k


Insider Transactions

Here are the insider transactions of stock shares related to Arecor Therapeutics PLC:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Amati Global Investors, Ltd.D2022-08-043.42k
Fazeli (Mohammad Sohail)Bought at price 3.65 per share.D2022-08-047.76k
Howell (Sarah Jennifer)Bought at price 3.65 per share.D2022-08-046.67k
Lombard Odier Asset Management (Europe) LimitedD2022-08-04
Lowther (Susan Day)Bought at price 3.65 per share.D2022-08-043.33k
Morgan (Jeremy)Bought at price 3.65 per share.D2022-08-046.67k
Oxford Technology 4 Vct PlcD2022-08-04763.33k
Richards (Andrew John Mc-Glashan)Bought at price 3.65 per share.D2022-08-046.67k
Soden (Christine)Bought at price 3.65 per share.D2022-08-046.67k
Unicorn Asset Management LtdD2022-08-0493.78k
Albion Capital Group LLPD2022-05-09
Amati Global Investors, Ltd.D2022-05-09
BGF Investment Management, Ltd.D2022-05-09
Calculus Capital LtdD2022-05-09
Chelverton Asset Management LtdD2022-05-09
Downing LLPD2022-05-09
Howell (Sarah Jennifer)D2022-05-09
Martin & Kathleen WoodD2022-05-09
Newton (Stewart)D2022-05-09
Unicorn Asset Management LtdD2022-05-09
Unilever PLCD2022-05-09
Fazeli (Mohammad Sohail)D2021-12-31
Howell (Sarah Jennifer)D2021-12-31
Lane (Andrew)D2021-12-31
Lowther (Susan Day)D2021-12-31
Morgan (Jeremy)D2021-12-31
Richards (Andrew John Mc-Glashan)D2021-12-31
Smith (Alan Edward)D2021-12-31
Soden (Christine)D2021-12-31
Gerring (David)Exercise of Option at price 0.01 per share.D2021-10-298.34k
Howell (Sarah Jennifer)Exercise of Option at price 0.01 per share.D2021-10-2951.66k
Jezek (Jan)Exercise of Option at price 0.01 per share.D2021-10-298.34k
Lawrence (Fiona)Exercise of Option at price 0.01 per share.D2021-10-294.17k
Lowther (Susan Day)Exercise of Option at price 0.01 per share.D2021-10-2925.83k
MacDonald-Clink (Jim)Exercise of Option at price 0.01 per share.D2021-10-2925k
Gerring (David)D2021-10-25
Howell (Sarah Jennifer)D2021-10-25
Jezek (Jan)D2021-10-25
Lawrence (Fiona)D2021-10-25
Lowther (Susan Day)D2021-10-25
Lowther (Susan Day)Bought at price 3.25 per share.D2021-06-2912.52k
Morgan (Jeremy)Bought at price 3.44 per share.D2021-06-0820.5k
Richards (Andrew John Mc-Glashan)Bought at price 3.44 per share.D2021-06-0812.5k
Soden (Christine)Bought at price 3.44 per share.D2021-06-0812.5k
Albion Capital Group LLPD2021-06-03
Amati Global Investors, Ltd.D2021-06-03
Amati Global Investors, Ltd.D2021-06-03
BGF Investment Management, Ltd.D2021-06-03
BGF Investment Management, Ltd.D2021-06-03
Calculus Capital LtdD2021-06-03
Chelverton Asset Management LtdD2021-06-03

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Arecor Therapeutics PLC. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Arecor Therapeutics PLC

Here is the result of two systematic investment strategies applied to Arecor Therapeutics PLC. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Arecor Therapeutics PLC

The following chart shows the equity curve of the two systematic investment strategies applied to Arecor Therapeutics PLC:

Arecor Therapeutics PLC automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 0.0% on the backtest period.

Performance at glance

Performance

0.0 %

Latent gain

0.0 £

Invested capital

410.0 £

Annualized return

0.0 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Arecor Therapeutics PLC

This is the result of two momentum investment strategies applied to Arecor Therapeutics PLC. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Arecor Therapeutics PLC

The following chart shows all the entries opened by the momentum investment system on Arecor Therapeutics PLC:

Arecor Therapeutics PLC momentum entries
  • The first momentum investment strategy would give 77.76% of return on Arecor Therapeutics PLC. That represents 179.35£ of latent gain with 230.65£ of employed capital.
  • The second momentum investment strategy would give 0% of return on Arecor Therapeutics PLC. That represents 0.0£ of latent gain with 0.0£ of employed capital.
Performance at glance (1Q Momentum)

Performance

77.76 %

Latent gain

179.35 £

Invested capital

230.65 £

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Momentum equity curve on Arecor Therapeutics PLC

The following chart shows the equity curve of the two momentum strategies applied to Arecor Therapeutics PLC:

Arecor Therapeutics PLC momentum equity

Note: the dividends potentially given by Arecor Therapeutics PLC are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Arecor Therapeutics PLC

The following chart shows the employed capital evolution of the two momentum strategies on Arecor Therapeutics PLC since the beginning:

Arecor Therapeutics PLC

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on Arecor Therapeutics PLC

Buy the dip entry openings on Arecor Therapeutics PLC

Arecor Therapeutics PLC

The performance achieved by the robo-advisor on Arecor Therapeutics PLC is 0%. That represents 0.0$ of latent gain with 0.0£ of employed capital. The following chart shows Arecor Therapeutics PLC stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Arecor Therapeutics PLC, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Equity curve of the strategy applied to Arecor Therapeutics PLC

The following chart shows the result of the investment strategy applied to Arecor Therapeutics PLC:

Arecor Therapeutics PLC

Note: the dividends potentially given by Arecor Therapeutics PLC are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Arecor Therapeutics PLC

The following chart shows the employed capital evolution since the beginning of the investment strategy on Arecor Therapeutics PLC:

Arecor Therapeutics PLC

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Arecor Therapeutics PLC

In this section, I will compare the three previous investment strategies applied to Arecor Therapeutics PLC.

Equity curve comparison on Arecor Therapeutics PLC

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Arecor Therapeutics PLC investment strategy comparison

Employed capital comparison on Arecor Therapeutics PLC

Arecor Therapeutics PLC investment comparison

Performance comparison on Arecor Therapeutics PLC

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 0.0% 0.0£ 410.0£ 0.0%
Momentum 1 quarter 77.76% 179.35£ 230.65£ 432.0%
Momentum 2 quarters 0% 0.0£ 0.0£ -0.0%
Non-directional 0% 0.0£ 0.0£ -0.0%
Annualized return comparison

Automatic investment

0.0 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Arecor Therapeutics PLC:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Arecor Therapeutics PLC and the other stocks. There may be false positives or some missing correlated stocks. If the price of Arecor Therapeutics PLC does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Arecor Therapeutics PLC
Country United Kingdom
City Little Chesterford
Address Chesterford Research Park
Phone 44 1223 426 060
Website arecor.com
FullTime employees 37
Industry Biotechnology
Sector Healthcare
Exchange XLON
Ticker AREC.XLON
Market www.londonstockexchange.com

Arecor Therapeutics PLC ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown